Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 15/20 | 0.44 |
| ▸ | CNR1 | P21554 | 14/20 | 0.44 |
| ▸ | ESR1 | P03372 | 2/20 | 0.36 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31545653 | 0.92 | CNR1 (0.44) | CNR2CNR1 | |
| SCHEMBL13825870 | 0.82 | CNR2 (0.44) | CNR2CNR1 | |
| SCHEMBL4567339 | 0.81 | CNR1 (0.46) | CNR2CNR1 | |
| SCHEMBL4570710 | 0.80 | CNR1 (0.36) | CNR2CNR1ESR1ESR2 | |
| SCHEMBL27861557 | 0.77 | HTR1D (0.48) | ESR1ESR2 | |
| SCHEMBL7942447 | 0.70 | CNR2 (0.61) | CNR2CNR1ESR1 | |
| SCHEMBL31545049 | 0.68 | ESR1 (0.36) | CNR2CNR1ESR1ESR2 | |
| SCHEMBL23490965 | 0.68 | CNR1 (0.55) | CNR2CNR1 | |
| SCHEMBL10938594 | 0.67 | CNR2 (0.58) | CNR2CNR1ESR1ESR2 | |
| SCHEMBL9742888 | 0.67 | ALDH1A1 (0.48) | ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173867-B2 | Treatment of immune dysregulation using cannabinoid derivatives | IMMUGEN PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | IMMUGEN PHARMACEUTICALS, INC. | 2014-03-06 | — | — | US | disclosed |
| US-8586767-B2 | Method for treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG RICK (US) | 2013-11-19 | — | — | US | disclosed |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | TRAVIS CRAIG RICK (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | TRAVIS CRAIG RICK (US) | 2012-05-17 | — | — | US | disclosed |
| US-20080108647-A1 | Treatment of HIV and diseases of immune dysregulation | TRAVIS CRAIG R | 2008-05-08 | — | — | US | disclosed |
| US-20070179135-A1 | Cannabinoid derivatives | TRAVIS CRAIG R | 2007-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140066497-A1 | TREATMENT OF IMMUNE DYSREGULATION USING CANNABINOID DERIVATIVES | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885ESR1 1655/4885 |
| US-20120289589-A1 | Treatment Of Immune Dysregulation Using Cannabinoid Derivatives | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885ESR1 1655/4885 |
| US-20120122917-A1 | Method For Treatment Of HIV And Diseases Of Immune Dysregulation | CNR2, CNR1, ICOS | CNR2 1/4885CNR1 2/4885ESR1 2266/4885 |
| US-20070179135-A1 | Cannabinoid derivatives | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885ESR1 978/4885 |
| US-20080108647-A1 | Treatment of HIV and diseases of immune dysregulation | CNR1, CNR2, ICOS | CNR2 2/4885CNR1 1/4885ESR1 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.